Grassley Seeks Meeting With Von Eschenbach To Assess Agency’s Drug Information Needs
This article was originally published in The Pink Sheet Daily
Executive Summary
Senator also asks Amgen CEO Sharer to brief his staff on EPO data allegedly withheld from the agency.
You may also be interested in...
New York Attorney General Probes Amgen Marketing Activities
Filing with Securities and Exchange Commission also reveals two shareholder legal actions against the firm.
New York Attorney General Probes Amgen Marketing Activities
Filing with Securities and Exchange Commission also reveals two shareholder legal actions against the firm.
ODAC Calls For Additional EPO Trials To Support Continued Use In Oncology
In the absence of data on approved therapeutic target, panel advises adding warnings from signals in off-label use to label.